Recro Hires Industry Veteran to Lead Business Development Team
Recro, a wholly owned subsidiary of Recro Pharma, Inc., and a leading provider of solid oral dose manufacturing services for the pharmaceutical industry, announces the hire of Heather N. Sugrue as head of business development, North America.
Recro is a contract development and manufacturing organization (CDMO) that specializes in extended release and controlled substances, offering capabilities in formulation development, analytical method development, manufacturing, and packaging and logistics.
Sugrue leads Recro’s North American business development executive team, driving new business and strengthening existing client relationships within the global pharmaceutical market. Conducting competitive intelligence to understand clients’ strategic objectives, she also functions as a liaison between clients and Recro’s internal teams, establishing a culture of cooperation and best practice sharing that drives success and aligns with the company’s customer-focused approach.
Prior to joining Recro, Sugrue spent five years as senior director of business development at Patheon, where she led the West Coast business development team across multiple business units, achieving consistent year-over-year growth. She also served as senior director of business development at Ricerca Biosciences and MDS Pharma Services. Sugrue has more than a decade of experience as an account manager at PerkinElmer, Invitrogen and Bio-Rad Laboratories and has received numerous awards. She earned a bachelor’s from Ithaca College and a master’s degree from Boston University, both in chemistry. “Heather is an industry veteran whose breadth and depth of experience is unparalleled, and she is integral to Recro’s long-term strategic initiatives as an expanding CDMO,” said Scott Rizzo, general manager of Recro. “She brings key leadership and coaching skills, thrives at building growth and has a talent for identifying client needs and establishing win-win relationships with organizations of any size.”
Recro provides solid dosage form development, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market. Specializing in extended release solid dose and DEA controlled substances, Recro has the experts to deliver clients’ most complex pharmaceutical development and manufacturing projects in its best-in-class, 97,000-square-foot manufacturing facility. For more information about Recro’s flexible CDMO solutions, visit www.recrogainesville.com.